GLP1R and diabetes mellitus: Fortunately, pharmacological interventions such as glucagon-like peptide-1 receptor agonists (GLP-1RA) that treat the obesity-diabetes-OSA triad can make substantial inroads in reversing the trends in morbidity and cost associated with obesity-related illnesses.